Results 201 to 210 of about 105,241 (264)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

SERAPHIM 2.0: an extended toolbox for studying phylogenetically informed movements. [PDF]

open access: yesBioinformatics
Dellicour S   +4 more
europepmc   +1 more source

Video-Based Motion Capture Smartphone Apps for Testing Human Motor Performance Skills: Scoping Review.

open access: yesJMIR Mhealth Uhealth
Zoeller CS   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy